title: [Dynamic contrast-enhanced MRI for evaluating bone marrow microcirculation in malignant hematological diseases before and after thalidomide therapy].
abstract: OBJECTIVE
  The aim of the study was to measure microcirculation parameters by dynamic contrast-enhanced MRI (d-MRI) and to evaluate the anti-angiogentic effects during treatment with thalidomide in different hematologic malignancies.
  
  
  METHODS
  In 20 healthy normal persons, 20 patients with myelodysplastic syndromes (MDS), 10 patients with multiple myeloma (MM) and 10 with myelofibrosis (MF) a fast gradient echo sequence (Turbo fast low angle shot 2D) with a pump controlled bolus infusion of gadolinium-DTPA was performed before and in 18 of these after beginning (average of 4.3 months) of a thalidomide therapy. Two pharmacokinetic parameters--the amplitude and exchange-rate-constant--were calculated and a statistical comparison of these values between healthy persons and patients as well as a correlation with the clinical course was executed.
  
  
  RESULTS
  Compared with the normal controls the patients showed a higher amplitude (normal persons 14.4 +/- 5.2, MDS 24.8 +/- 8.1, MF 35.9 +/- 4.3, MM 23.4 +/- 3.6) and exchange-rate-constant (normal persons 0.124 +/- 0.042, MDS 0.136 +/- 0.036, MF 0.144 +/- 0.068, MM 0.131 +/- 0.034). In the d-MRI-follow-up examinations a significant (p < 0.005) reduction of the amplitude and exchange rate constant values was evident in 14 of 18 patients undergoing a thalidomide therapy. Clinically all of these patients showed a therapy responding with complete or partial diseases remission.
  
  
  CONCLUSIONS
  In patients with hematologic malignancies significantly higher d-MRI-microcirculation parameters of the lumbar spine can be demonstrated than in normal persons. During anti-angiogenetic treatment with thalidomide a decrease of these values was observed in case of a responding to therapy.
authors.affiliation: Institut für Diagnostische Radiologie, Heinrich-Heine Universität, Moorenstrasse 5, 40225 Düsseldorf. scherera@uni-duesseldorf.de
authors.forename: A
authors.initials: A
authors.lastname: Scherer
authors.forename: C
authors.initials: C
authors.lastname: Strupp
authors.forename: H J
authors.initials: HJ
authors.lastname: Wittsack
authors.forename: V
authors.initials: V
authors.lastname: Engelbrecht
authors.forename: R
authors.initials: R
authors.lastname: Willers
authors.forename: U
authors.initials: U
authors.lastname: Germing
authors.forename: N
authors.initials: N
authors.lastname: Gattermann
authors.forename: R
authors.initials: R
authors.lastname: Haas
authors.forename: U
authors.initials: U
authors.lastname: Mödder
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D001853:Bone Marrow / Q000098:blood supply*; D003287:Contrast Media; D005260:Female; D019786:Gadolinium DTPA; D006801:Humans; D007089:Image Enhancement; D007091:Image Processing, Computer-Assisted; D008159:Lumbar Vertebrae / Q000098:blood supply; D008279:Magnetic Resonance Imaging; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis / Q000188:drug therapy*; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000175:diagnosis / Q000188:drug therapy*; D055728:Primary Myelofibrosis / Q000175:diagnosis / Q000188:drug therapy*; D013792:Thalidomide / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D003287:Contrast Media; D013792:Thalidomide; D019786:Gadolinium DTPA